{"id":451,"date":"2026-04-20T20:40:35","date_gmt":"2026-04-20T19:40:35","guid":{"rendered":"https:\/\/hcp.cingal.com\/?page_id=451"},"modified":"2026-09-01T12:27:01","modified_gmt":"2026-09-01T11:27:01","slug":"trials-studies","status":"publish","type":"page","link":"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/trials-studies\/","title":{"rendered":"Klinische Studien &amp; Untersuchungen"},"content":{"rendered":"<nav class=\"sub-navigation-block acf-block section-padding-3xl sub-navigation-block--sticky align wp-block-acf-sub-navigation\" data-block=\"sub-navigation\" data-block-title=\"Sub Navigation Row\" data-sticky=\"true\" aria-label=\"Seitenbereichsnavigation\" data-detect-dark-bg=\"true\">\n\t<div class=\"sub-nav__select-wrap\">\n\t\t<select class=\"sub-nav__select\" aria-label=\"Seitenbereichsnavigation\">\n\t\t\t\t\t\t\t\t\t\t\t<option value=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/trials-studies\/\" selected>\n\t\t\t\t\tKlinische Studien &amp; Untersuchungen\t\t\t\t<\/option>\n\t\t\t\t\t\t\t\t\t\t\t<option value=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/real-world-data\/\" >\n\t\t\t\t\tWirtschaftliche Modellierung &amp; Kosten-Nutzen-Analyse\t\t\t\t<\/option>\n\t\t\t\t\t\t\t\t\t\t\t<option value=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/safety-profile\/\" >\n\t\t\t\t\tWiederholte Injektionen und Sicherheit\t\t\t\t<\/option>\n\t\t\t\t\t\t\t\t\t\t\t<option value=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/clinical-papers-publications\/\" >\n\t\t\t\t\tKlinische Berichte &amp; Publikationen\t\t\t\t<\/option>\n\t\t\t\t\t<\/select>\n\t<\/div>\n\t<div class=\"sub-nav__dropdown\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"sub-nav__inner\">\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<ul class=\"sub-nav__list\" role=\"list\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"sub-nav__item\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/trials-studies\/\"\n\t\t\t\t\t\t\t\t   class=\"sub-nav__link\"\n\t\t\t\t\t\t\t\t   \t\t\t\t\t\t\t\t   >\n\t\t\t\t\t\t\t\t\tKlinische Studien &amp; Untersuchungen\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"sub-nav__item\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/real-world-data\/\"\n\t\t\t\t\t\t\t\t   class=\"sub-nav__link\"\n\t\t\t\t\t\t\t\t   \t\t\t\t\t\t\t\t   >\n\t\t\t\t\t\t\t\t\tWirtschaftliche Modellierung &amp; Kosten-Nutzen-Analyse\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"sub-nav__item\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/safety-profile\/\"\n\t\t\t\t\t\t\t\t   class=\"sub-nav__link\"\n\t\t\t\t\t\t\t\t   \t\t\t\t\t\t\t\t   >\n\t\t\t\t\t\t\t\t\tWiederholte Injektionen und Sicherheit\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"sub-nav__item\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/hcp.cingal.com\/de\/clinical-evidence\/clinical-papers-publications\/\"\n\t\t\t\t\t\t\t\t   class=\"sub-nav__link\"\n\t\t\t\t\t\t\t\t   \t\t\t\t\t\t\t\t   >\n\t\t\t\t\t\t\t\t\tKlinische Berichte &amp; Publikationen\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/nav>\n\n\n\n<section class=\"hero hero-animate acf-block section-padding-3xl hero-content-left hero-has-table has-default-bg has-dark-bg align wp-block-acf-hero\" data-block=\"hero\" data-block-title=\"Hero Section\" data-detect-dark-bg=\"true\">\n     \n     <div class=\"container\">\n                    <!-- Content left\/right with side-aligned image -->\n          <div class=\"row hero-wrapper\">\n               \n               <div class=\"col-6 col-sm-12 hero-content\">\n                    <h1>Umfangreiche Evidenz bei Kniearthrose<\/h1>\n\n<div class=\"hero-description\"><p>Die klinische Grundlage von Cingal basiert auf mehreren randomisierten, kontrollierten klinischen Studien der Phase III, die bei Patienten mit Kniearthrose durchgef\u00fchrt wurden.<\/p>\n<\/div>\n\n<div class=\"hero-ctas\">\n     <a href=\"#outcome-data\" class=\"btn btn-light hero-primary-cta\">Zu den Ergebnisdaten springen<\/a><\/div>\n               <\/div>\n\n                              <!-- Content on left, data table on right -->\n               <div class=\"col-6 col-sm-12 hero-table-col\">\n                    <div class=\"hero-table has-nested-bg\">\n                                                  <p class=\"hero-table__title\">Pivotalstudie im \u00dcberblick: Studie 13-01<\/p>\n                                                  <table class=\"hero-table__table\">\n                              <tbody>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Design<\/th>\n                                        <td class=\"hero-table__value\">Randomisierte, doppelblinde, multizentrische Phase-III-<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Patienten<\/th>\n                                        <td class=\"hero-table__value\">368<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Bev\u00f6lkerung<\/th>\n                                        <td class=\"hero-table__value\">Kniearthrose, KL-Grad I\u2013III<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Nachfassaktion<\/th>\n                                        <td class=\"hero-table__value\">26 Wochen<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Prim\u00e4rer Endpunkt<\/th>\n                                        <td class=\"hero-table__value\">WOMAC-Schmerzscore<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Komparatoren<\/th>\n                                        <td class=\"hero-table__value\">HA allein \u00b7 Kochsalzl\u00f6sung<\/td>\n                                   <\/tr>\n                                                                      <tr class=\"hero-table__row\">\n                                        <th class=\"hero-table__label\" scope=\"row\">Referenz<\/th>\n                                        <td class=\"hero-table__value\">Hangody et al., Cartilage 2018<\/td>\n                                   <\/tr>\n                                                                 <\/tbody>\n                         <\/table>\n                    <\/div>\n               <\/div>\n                         <\/div>\n               <\/div>\n<\/section>\n\n\n\n<section class=\"icon-text-box-grid-section layout-side-by-side media-size-icon acf-block section-padding-3xl align wp-block-acf-icon-text-box-grid has-background has-blue-light-background-color\" data-block=\"icon-text-box-grid\" data-block-title=\"Icon &amp; Text Box Grid\" data-detect-dark-bg=\"true\">\n    <div class=\"row icon-text-box-grid container\">\n                    <!-- Side-by-side layouts: Heading left, icon grid or icon list right -->\n                            <div class=\"col-5 col-md-12 section-header section-header--left\">\n                                            <h2 class=\"section-title\">Drei Phase-III-Studien<\/h2>\n                    \n                    \n                    \n                                    <\/div>\n            \n                            <div class=\"col-7 col-md-12 icon-grid-container\">\n                    <div class=\"row icon-grid-inner\">\n                            <div class=\"col-6 col-md-6 col-sm-12\">\n                \n                    <h3 class=\"box-title h5\">Studiendesign und Vergleichsgruppen<\/h3>\n        \n                    <div class=\"box-description\"><ul>\n<li>Randomisierte, doppelblinde, multizentrische Phase-III-Studien<\/li>\n<li>Vergleich von Cingal mit drei Wirkstoffen und einem Placebo:\n<ul>\n<li>vs. Hyalurons\u00e4ure allein<sup>1<\/sup><\/li>\n<li>im Vergleich zu Triamcinolonhexacetonid allein<sup>2<\/sup><\/li>\n<li>im Vergleich zu Kochsalzl\u00f6sung (Placebo-Kontrolle)<sup>3<\/sup><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n        \n            <\/div>\n        <div class=\"col-6 col-md-6 col-sm-12\">\n                \n                    <h3 class=\"box-title h5\">Nachgewiesene Ergebnisse<\/h3>\n        \n                    <div class=\"box-description\"><ul>\n<li><strong>Schnelle Schmerzlinderung<\/strong> (bereits in Woche 1)<\/li>\n<li><strong>Nachhaltige Verbesserungen<\/strong> bis zur 26. Woche<\/li>\n<li>Statistisch signifikante Verbesserungen bei <strong>Schmerz, Steifheit und Funktion<\/strong> (WOMAC)<\/li>\n<li><strong>Schnelleres Einsetzen der Linderung<\/strong> im Vergleich zu HA allein<\/li>\n<li>\u00dcberlegenheit im Vergleich zur Kochsalzkontrolle <strong>at measured time points<\/strong><\/li>\n<li><strong>92% OMERACT-OARSI-Ansprechrate<\/strong> in der 26. Woche<\/li>\n<\/ul>\n<\/div>\n        \n            <\/div>\n                        <\/div>\n                <\/div>\n            \n        \n        \n            <\/div>\n<\/section>\n\n\n\n<section class=\"wp-block-acf-flexible-content-area flexible-content-area-block section-padding-3xl\" data-block=\"flexible-content-area\" data-block-title=\"Flexible Content Area\"><div class=\"flexible-content-inner container\"><div class=\"flexible-content-wrapper\">\n<section style=\"padding-bottom:var(--wp--preset--spacing--md)\" class=\"two-column-content acf-block section-padding-3xl align-items-top align wide-gap-columns wp-block-acf-two-column-content\" data-block=\"two-column-content\" data-block-title=\"Two-Column Content\" data-detect-dark-bg=\"true\">\n     <div class=\"two-column-content__container container\">\n                    <div class=\"row two-column-content__grid\">\n                              <div class=\"col-7 col-sm-12 two-column-content__column two-column-content__column--left flex-col\">\n                                        <div class=\"two-column-content__content\">\n                         <h3>Eine multizentrische Studie zeigte eine durchg\u00e4ngige Verbesserung bei allen Endpunkten<\/h3>\n<p>In der zulassungsrelevanten Phase-III-Studie (368 Patienten, KL-Grade I\u2013III) wurde Cingal \u00fcber einen Zeitraum von 26 Wochen mit Kochsalzl\u00f6sung, HA allein und TH allein verglichen. Die Ergebnisse zeigten bereits ab Woche 1 statistisch signifikante Verbesserungen hinsichtlich Schmerzen, Steifigkeit und k\u00f6rperlicher Funktionsf\u00e4higkeit.<\/p>\n<p>Die WOMAC-Gesamtskala erfasste Verbesserungen in den Bereichen Schmerz, Steifigkeit und k\u00f6rperliche Funktion \u2013 den drei f\u00fcr die Lebensqualit\u00e4t von Patienten mit Knie-OA relevantesten Dimensionen.<\/p>\n                    <\/div>\n                                                       <\/div>\n               \n                              <div class=\"col-5 col-sm-12 two-column-content__column two-column-content__column--right flex-col\">\n                                        <div class=\"two-column-content__content\">\n                         <h3 class=\"h5\">Studienprofil: Cingal 13-01<\/h3>\n<ul>\n<li>Randomisiert, doppelblind, placebokontrolliert<\/li>\n<li>368 Patienten wurden in die Studie aufgenommen<\/li>\n<li>Kniegelenkarthrose, Kellgren-Lawrence-Grade I\u2013III<\/li>\n<li>Prim\u00e4rer Endpunkt: WOMAC-Schmerzscore nach 26 Wochen<\/li>\n<li>Sekund\u00e4rer Endpunkt: OMERACT-OARSI-Responderrate<\/li>\n<li>Nachuntersuchung: 26 Wochen<\/li>\n<\/ul>\n                    <\/div>\n                                                       <\/div>\n                         <\/div>\n     <\/div>\n<\/section>\n\n\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-d7854776 wp-block-group-is-layout-constrained\">\n<section style=\"padding-top:var(--wp--preset--spacing--0);padding-bottom:var(--wp--preset--spacing--0)\" class=\"statistics-row-block acf-block section-padding-3xl align wide-gap-columns wp-block-acf-statistics-row\" data-detect-dark-bg=\"true\" data-block=\"statistics-row\" data-block-title=\"Statistics Row\">\n\t<div class=\"statistics-row-container container\">\n\t\t<div class=\"statistics-row-content\">\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistics-grid animate-stagger statistics-grid--divided-rows\" data-metric-size=\"md\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-item statistic-item--row\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"statistic-metric h1\">Woche 1<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-label\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"statistic-title h6\">Schneller Eintritt der Schmerzlinderung<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-text\"><p>Eine signifikante Verbesserung der Schmerzwerte wurde bereits in Woche 1 beobachtet, mit einem schnelleren Einsetzen der Linderung im Vergleich zu Hyalurons\u00e4ure allein, was einen klinisch bedeutsamen Unterschied f\u00fcr Patienten darstellt, die auf eine Symptomkontrolle warten.<\/p>\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-item statistic-item--row\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"statistic-metric h1\">72%<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-label\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"statistic-title h6\">Verbesserung der WOMAC-Schmerzen<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-text\"><p>Verbesserung des WOMAC-Schmerzindex nach 26 Wochen. WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) ist das validierte, patientenberichtete Ergebnismessinstrument f\u00fcr OA-Schmerzen, -Steifheit und -k\u00f6rperliche Funktion.<\/p>\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-item statistic-item--row\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"statistic-metric h1\">92%<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-label\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"statistic-title h6\">OMERACT-OARSI-Responder nach 26 Wochen<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-text\"><p>OMERACT-OARSI ist das validierte Kriterium zur Bestimmung des Ansprechens in klinischen Studien zur Arthrose. Eine 92%-Ansprechrate nach 26 Wochen belegt sowohl ein dauerhaftes Ansprechen als auch eine hohe klinische Relevanz auf Patientenebene.<\/p>\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-item statistic-item--row\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"statistic-metric h1\">\u00dcberlegenheit<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-label\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"statistic-title h6\">Gemessene Zeitpunkte vs. Kochsalzl\u00f6sung<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"statistic-text\"><p>Cingal zeigte \u00fcber den gesamten 26-w\u00f6chigen Nachbeobachtungszeitraum hinweg zu den gemessenen Zeitpunkten eine \u00dcberlegenheit gegen\u00fcber der Kochsalzl\u00f6sungskontrolle, was eine konsistente und anhaltende Wirksamkeit gegen\u00fcber dem Placebo best\u00e4tigte.<\/p>\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\n\t\t\t\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/section>\n<\/div>\n<\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-acf-flexible-content-area flexible-content-area-block section-padding-3xl has-gray-light-background-color has-background\" data-block=\"flexible-content-area\" data-block-title=\"Flexible Content Area\" id=\"outcome-data\"><div class=\"flexible-content-inner container\"><div class=\"flexible-content-wrapper\">\n<h2 class=\"wp-block-heading\">Klinische Ergebnisdiagramme<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Die folgenden Diagramme veranschaulichen die Wirksamkeitsergebnisse der zulassungsrelevanten Phase-III-Studie (Studie 13-01).<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9ba6dbca wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-group has-white-background-color has-background is-layout-flow wp-container-core-group-is-layout-2c7d62e0 wp-block-group-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--md);padding-right:var(--wp--preset--spacing--md);padding-bottom:var(--wp--preset--spacing--md);padding-left:var(--wp--preset--spacing--md)\" data-detect-dark-bg=\"true\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1152\" height=\"1689\" src=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp\" alt=\"Line graph showing WOMAC pain score reduction over 26 weeks, with Cingal achieving approximately 60-70% reduction compared to 35-50% for other single injection products.\" class=\"wp-image-2118\" srcset=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp 1152w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart-205x300.webp 205w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart-698x1024.webp 698w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart-768x1126.webp 768w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart-1048x1536.webp 1048w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart-8x12.webp 8w\" sizes=\"(max-width: 1152px) 100vw, 1152px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-group has-white-background-color has-background is-layout-flow wp-container-core-group-is-layout-2c7d62e0 wp-block-group-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--md);padding-right:var(--wp--preset--spacing--md);padding-bottom:var(--wp--preset--spacing--md);padding-left:var(--wp--preset--spacing--md)\" data-detect-dark-bg=\"true\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1152\" height=\"1692\" src=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate.webp\" alt=\"Infographic showing 89% of patients responded to Cingal at Week 1 and 92% at Week 26, illustrated with human figure icons in green and blue respectively.\" class=\"wp-image-2117\" srcset=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate.webp 1152w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate-204x300.webp 204w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate-697x1024.webp 697w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate-768x1128.webp 768w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate-1046x1536.webp 1046w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/omeract-oarsi-responder-rate-8x12.webp 8w\" sizes=\"(max-width: 1152px) 100vw, 1152px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-group has-white-background-color has-background is-layout-flow wp-container-core-group-is-layout-2c7d62e0 wp-block-group-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--md);padding-right:var(--wp--preset--spacing--md);padding-bottom:var(--wp--preset--spacing--md);padding-left:var(--wp--preset--spacing--md)\" data-detect-dark-bg=\"true\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1152\" height=\"1692\" src=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26.webp\" alt=\"Chart showing WOMAC pain reduction results: 59% at week 1 and 72% at week 26 for Cingal treatment, displayed with green and blue icons and arrows.\" class=\"wp-image-2116\" srcset=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26.webp 1152w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26-204x300.webp 204w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26-697x1024.webp 697w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26-768x1128.webp 768w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26-1046x1536.webp 1046w, https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/pain-reduction-week1-week26-8x12.webp 8w\" sizes=\"(max-width: 1152px) 100vw, 1152px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/section>\n\n\n\n\n\n\n\n\n<section class=\"references-dropdown section-padding-lg align wp-block-acf-references-dropdown\" id=\"references\" data-block=\"references-dropdown\" data-block-title=\"References Dropdown\" data-detect-dark-bg=\"true\">\n\t<div class=\"container\">\n\t\t<div class=\"references-dropdown__container has-nested-bg\">\n\t\t<button\n\t\t\ttype=\"button\"\n\t\t\tclass=\"references-dropdown__header\"\n\t\t\tid=\"references-6a972467e2811-btn\"\n\t\t\taria-expanded=\"false\"\n\t\t\taria-controls=\"references-6a972467e2811-panel\"\n\t\t>\n\t\t\t<span class=\"references-dropdown__header-content\">\n\t\t\t\t<img\n\t\t\t\t\tsrc=\"https:\/\/hcp.cingal.com\/wp-content\/themes\/3mw-core-child\/blocks\/references-dropdown\/icon-references.svg\"\n\t\t\t\t\tclass=\"references-dropdown__icon\"\n\t\t\t\t\twidth=\"30\"\n\t\t\t\t\theight=\"37\"\n\t\t\t\t\talt=\"\"\n\t\t\t\t\taria-hidden=\"true\"\n\t\t\t\t>\n\t\t\t\t<span class=\"references-dropdown__title\">Referenzen<\/span>\n\t\t\t<\/span>\n\t\t\t<span class=\"references-dropdown__toggle\" aria-hidden=\"true\">\n\t\t\t\t<svg class=\"references-dropdown__toggle-icon references-dropdown__toggle-icon--plus\" width=\"24\" height=\"24\" viewbox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t\t<path d=\"M12 5V19\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n\t\t\t\t\t<path d=\"M5 12H19\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n\t\t\t\t<\/svg>\n\t\t\t\t<svg class=\"references-dropdown__toggle-icon references-dropdown__toggle-icon--close\" width=\"24\" height=\"24\" viewbox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t\t<path d=\"M18 6L6 18\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n\t\t\t\t\t<path d=\"M6 6L18 18\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n\t\t\t\t<\/svg>\n\t\t\t<\/span>\n\t\t<\/button>\n\t\t<div\n\t\t\tclass=\"references-dropdown__panel\"\n\t\t\tid=\"references-6a972467e2811-panel\"\n\t\t\trole=\"region\"\n\t\t\taria-labelledby=\"references-6a972467e2811-btn\"\n\t\t\thidden\t\t>\n\t\t\t<div class=\"references-dropdown__content\">\n\t\t\t\t<ol>\n<li>Hangody L. et al. Intraartikul\u00e4re Injektion eines vernetzten Natriumhyaluronats in Kombination mit Triamcinolonhexacetonid (Cingal) zur Linderung der Symptome bei Kniegelenksarthrose: eine randomisierte, doppelblinde, placebokontrollierte multizentrische klinische Studie.<span>\u00a0<\/span><em>Knorpel.<\/em><span>\u00a0<\/span>2018 Jul;9(3):276-283. doi: 10.1177\/1947603517703732. PMID: 28535076; PMCID: PMC6042027.<span>\u00a0<\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6042027\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6042027\/<\/a><\/li>\n<li class=\"references-list__item\">Daten zu Akte 16-02.<\/li>\n<li class=\"references-list__item\">Daten zu Akte 19-01.<\/li>\n<li>Alle Abbildungen: Hangody L. et al. Intraartikul\u00e4re Injektion eines vernetzten Natriumhyaluronats in Kombination mit Triamcinolonhexacetonid (Cingal) zur Linderung der Symptome einer Kniegelenksarthrose: eine randomisierte, doppelblinde, placebokontrollierte multizentrische klinische Studie. Cartilage. Juli 2018; 9(3):276\u2013283. doi: 10.1177\/1947603517703732. PMID: 28535076; PMCID: PMC6042027. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6042027\" target=\"_blank\" rel=\"noopener\">pmc.ncbi.nlm.nih.gov\/articles\/PMC6042027<\/a><\/li>\n<\/ol>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":441,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-451","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cingal Clinical Trials: Phase III Design and Outcomes<\/title>\n<meta name=\"description\" content=\"Cingal&#039;s pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.cingal.com\/de\/klinische-evidenz\/trials-studies\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cingal Clinical Trials: Phase III Design and Outcomes\" \/>\n<meta property=\"og:description\" content=\"Cingal&#039;s pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.cingal.com\/de\/klinische-evidenz\/trials-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Cingal for Healthcare Professionals\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T11:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/\",\"url\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/\",\"name\":\"Cingal Clinical Trials: Phase III Design and Outcomes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/hcp.cingal.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/08\\\/womac-pain-chart.webp\",\"datePublished\":\"2026-04-20T19:40:35+00:00\",\"dateModified\":\"2026-09-01T11:27:01+00:00\",\"description\":\"Cingal's pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/hcp.cingal.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/08\\\/womac-pain-chart.webp\",\"contentUrl\":\"https:\\\/\\\/hcp.cingal.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/08\\\/womac-pain-chart.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/trials-studies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hcp.cingal.com\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Evidence\",\"item\":\"https:\\\/\\\/hcp.cingal.com\\\/clinical-evidence\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Trials &amp; Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#website\",\"url\":\"https:\\\/\\\/hcp.cingal.com\\\/\",\"name\":\"Cingal for Healthcare Professionals\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hcp.cingal.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#organization\",\"name\":\"Anika\",\"url\":\"https:\\\/\\\/hcp.cingal.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/hcp.cingal.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/04\\\/Anika-Logo-Placeholder.png\",\"contentUrl\":\"https:\\\/\\\/hcp.cingal.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/04\\\/Anika-Logo-Placeholder.png\",\"width\":1200,\"height\":627,\"caption\":\"Anika\"},\"image\":{\"@id\":\"https:\\\/\\\/hcp.cingal.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cingal Clinical Trials: Phase III Design and Outcomes","description":"Cingal's pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.cingal.com\/de\/klinische-evidenz\/trials-studies\/","og_locale":"de_DE","og_type":"article","og_title":"Cingal Clinical Trials: Phase III Design and Outcomes","og_description":"Cingal's pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline","og_url":"https:\/\/hcp.cingal.com\/de\/klinische-evidenz\/trials-studies\/","og_site_name":"Cingal for Healthcare Professionals","article_modified_time":"2026-09-01T11:27:01+00:00","og_image":[{"url":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/","url":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/","name":"Cingal Clinical Trials: Phase III Design and Outcomes","isPartOf":{"@id":"https:\/\/hcp.cingal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/#primaryimage"},"image":{"@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp","datePublished":"2026-04-20T19:40:35+00:00","dateModified":"2026-09-01T11:27:01+00:00","description":"Cingal's pivotal Phase III trial (n=368): 72% WOMAC pain improvement and 92% OMERACT-OARSI response at 26 weeks vs. HA, TH, and saline","breadcrumb":{"@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/#primaryimage","url":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp","contentUrl":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/08\/womac-pain-chart.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.cingal.com\/clinical-evidence\/trials-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.cingal.com\/home\/"},{"@type":"ListItem","position":2,"name":"Clinical Evidence","item":"https:\/\/hcp.cingal.com\/clinical-evidence\/"},{"@type":"ListItem","position":3,"name":"Clinical Trials &amp; Studies"}]},{"@type":"WebSite","@id":"https:\/\/hcp.cingal.com\/#website","url":"https:\/\/hcp.cingal.com\/","name":"Cingal f\u00fcr medizinisches Fachpersonal","description":"","publisher":{"@id":"https:\/\/hcp.cingal.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.cingal.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/hcp.cingal.com\/#organization","name":"Anika","url":"https:\/\/hcp.cingal.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/hcp.cingal.com\/#\/schema\/logo\/image\/","url":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/04\/Anika-Logo-Placeholder.png","contentUrl":"https:\/\/hcp.cingal.com\/wp-content\/uploads\/sites\/2\/2026\/04\/Anika-Logo-Placeholder.png","width":1200,"height":627,"caption":"Anika"},"image":{"@id":"https:\/\/hcp.cingal.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/pages\/451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":10,"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/pages\/451\/revisions"}],"predecessor-version":[{"id":2584,"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/pages\/451\/revisions\/2584"}],"up":[{"embeddable":true,"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/pages\/441"}],"wp:attachment":[{"href":"https:\/\/hcp.cingal.com\/de\/wp-json\/wp\/v2\/media?parent=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}